November/December 2015

Feature

Perspectives

Formulary Decisions and the Evolution of Psoriasis Treatment

12/14/2015

Abstract: Psoriasis is a common and significant illness characterized by systemic inflammation. In its mildest form, psoriasis can often be managed with relatively low-cost topical therapies; but for...

...

12/14/2015

Journal of Clinical Pathways

Research Reports

A Clinical Pathway to Reduce Time to Antibiotic Administration in Pediatric Cancer Patients With Fever and Potential Neutropenia

12/14/2015

Susan Lindemulder , MD, MCR;

Thuan Nguyen , MD, PhD;

Adam Lamble , MD;

David M. Spiro , MD, MPH;

Dawn Nolt , MD, MPH;

Linda C. Stork , MD;

Suman Malempati , MD;

Abstract: The authors developed a novel clinical pathway in the pediatric emergency department (PED) of Doernbecher Children’s Hospital, Oregon Health & Science University, that endorses administering...

...

12/14/2015

Journal of Clinical Pathways

Column

Counterpoint

When Determining Value in Cancer Care, Don`t Forget the Patient

12/14/2015

Joan S. McClure , MS;

Al B. Benson III, MD, FACP, FASCO;

Before the relative value of a drug can be determined, one must first consider how value is defined by the patient. Cancer care is expensive, and evaluating costs in cancer care is complex. Drug costs are only part...

Before...

12/14/2015

Journal of Clinical Pathways

Viewpoint

Overcoming the Political and Economic Roadblocks Stopping Effective Comparative Drug Evaluation

12/14/2015

Roger Longman , MA;

Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of the resistance of drug companies and payers, stakeholders are finding other tools to help...

...

12/14/2015

Journal of Clinical Pathways

Clinical Pathways GPS

The Place for Biosimilars in Clinical Pathways

12/14/2015

Scott Guerin , PhD;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Payers and at-risk providers are developing clinical pathways with great specificity regarding the preferred drugs that be used. Increasingly, these pathways will include biosimilar products. There are three major...

Payers...

12/14/2015

Journal of Clinical Pathways

Insights

Interview

A Clinical Pathway for Transcatheter Aortic Valve Replacement

12/14/2015

More and more, various health care institutions around the country are implementing clinical pathways in an effort to improve outcomes and control costs. A 2003 study reported that more than 80% of hospitals had implemented clinical...

More and more, various...

12/14/2015

Journal of Clinical Pathways

Interview

Evidence Blocks to Evaluate the Relative Value of Oncology Treatments

12/14/2015

Many institutions and health care professionals have been aware of the staggering rise of health care costs. An IMS Health report published in May of 2015 confirmed that drug sales in the United States surpassed $100...

Many...

12/14/2015

Journal of Clinical Pathways

Department

Research in Review

Routine Imaging for DLBCL Post-Remission Does Not Improve Survival

12/14/2015

JCP Editors

Routine imaging for diffuse large B-cell lymphoma (DLBCL) in patients after first complete remission does not translate into better survival, suggests a study in the online Journal of Clinical Oncology. Considering...

...

12/14/2015

Journal of Clinical Pathways

Research in Review

Circulating Tumor DNA in Blood Used to Track Cancer Treatment Outcomes

12/11/2015

JCP Editors

Two new studies suggest a role for blood tests, or liquid biopsies, in guiding a patient’s cancer treatment. The research, which involved patients with breast and prostate cancers, scanned blood for traces of...

Two...

12/11/2015

Journal of Clinical Pathways

Research in Review

ASCO Updates Antiemetic Guidelines to Include New Agent

12/11/2015

JCP Editors

The American Society of Clinical Oncology (ASCO) issued updated antiemetic guidelines recommending that patients who receive highly emetogenic chemotherapy regimens be offered a 3-drug combination of a neurokinin 1...

The...

12/11/2015

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Editorial Correspondence

November/December 2015

Feature

Column

Insights

Department

Current Issue

Special Reports

Subscribe

November 2015 Volume 1

Specialties

Events

Year Round Education

HMP Global Products